Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose
Journal article published in 2022 by
Katarzyna Krzywicka 
,
Anita van de Munckhof ,
Julian Zimmermann ,
Felix J. Bode ,
Giovanni Frisullo ,
Theodoros Karapanayiotides ,
Bernd Pötzsch,
Mayte Sánchez van Kammen,
Mirjam R. Heldner ,
Marcel Arnold,
Johanna A. Kremer Hovinga ,
José M. Ferro ,
Diana Aguiar de Sousa ,
Jonathan M. Coutinho
,
Anita van de Munckhof ,
Julian Zimmermann ,
Felix J. Bode ,
Giovanni Frisullo ,
Theodoros Karapanayiotides ,
Bernd Pötzsch,
Mayte Sánchez van Kammen,
Mirjam R. Heldner ,
Marcel Arnold,
Johanna A. Kremer Hovinga ,
José M. Ferro ,
Diana Aguiar de Sousa ,
Jonathan M. Coutinho
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but life-threatening complication of adenoviral vaccination against COVID-19, has been reported almost entirely following the first dose. Krzywicka and colleagues report on 124 patients with VITT in a multinational registry diagnosed after dose 2; no specific events were observed after dose 1. These patients had early presentation, and two of the patients died.